Pharming Gains Nod from EMA on PIP for Leniolisib

Article

Pharming Group, has been granted a positive opinion by EMA for its Paediatric Investigation Plan for leniolisib.

Commercial-stage biopharmaceutical company, Pharming Group, has been granted a positive opinion by the European Medicines Agency (EMA) for its Paediatric Investigation Plan (PIP) for leniolisib.

Leniolisib is a phosphoinositide 3-kinase (PI3K) inhibitor that Pharming is currently developing for the treatment of activated PI3K delta syndrome (APDS). So far, patients aged 12 years and older have been included in the ongoing registration of the Phase II/III study evaluating the therapy. However, as APDS affects younger children as well, the PIP, that has been agreed upon by EMA, will enable the company to enroll children as young as one-year old in future studies.

Once the agreed upon PIP has been successfully completed, the market exclusivity for leniolisib could be extended for a further two years in the European Union, which would be on top of the original 10-year market exclusivity the therapy has as a result of its EU Orphan Drug Designation. The company anticipates the top-line data from the Phase II/III registration in the first quarter of 2022.

“We are pleased to have received a positive PIP decision from EMA and accomplish this important regulatory milestone as we continue to advance leniolisib for the treatment of APDS in Europe as well as globally,” said Anurag Relan, chief medical officer of Pharming in a Jan. 6, 2022 press release. “The approval of the PIP further supports our confidence in the potential of leniolisib to address this orphan disease and population and provides us with a pathway towards marketing approval in Europe, in parallel with our [United States] regulatory strategy. Moving forward, we look forward to continuing to work with the regulatory authorities to bring leniolisib to the European market as expeditiously as possible.”

Source: Pharming

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes